ProfileGDS5678 / 1425933_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 80% 79% 80% 78% 76% 81% 80% 78% 80% 79% 79% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2804178
GSM967853U87-EV human glioblastoma xenograft - Control 25.6261380
GSM967854U87-EV human glioblastoma xenograft - Control 35.4547579
GSM967855U87-EV human glioblastoma xenograft - Control 45.8119380
GSM967856U87-EV human glioblastoma xenograft - Control 55.3620778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9855476
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6500181
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6176780
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3377678
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7516380
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5288879
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5474279
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4394179
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5679780